Sara Demy, CEO of Demy-Colton, hosts interactive virtual salons featuring industry leaders and distinguished guests exploring today’s most consequential and disruptive topics in healthcare.
U.S. MARKET ACCESS STRATEGY AT THE CLINICAL STAGE FOR ALL COMPANIES CONSIDERING A LAUNCH: A Three-Part Series
The complexity of the U.S. market access landscape means that proving safety and efficacy is no longer a guarantee of commercial success. This three-part series will provide you with the basics of government and commercial payer rules, walk through hypotheticals that bring those rules to life, and prepare you for the market’s evolving focus on value-delivery. At the end of the series, you will understand why your market access strategy can and should start before the initiation of your Phase IIIs, have identified early-stage steps to de-risk those variables with the potential to constrain market access later, and why you should be prepared for investors to ask you these same questions. This series will benefit any company new to the U.S. market, or looking to launch in the U.S.
The complexity of the U.S. market access landscape means that proving safety and efficacy is no longer a guarantee of commercial success. This three-part series will provide you with the basics of government and commercial payer rules, walk through hypotheticals that bring those rules to life, and prepare you for the market’s evolving focus on value-delivery. At the end of the series, you will understand why your market access strategy can and should start before the initiation of your Phase IIIs, have identified early-stage steps to de-risk those variables with the potential to constrain market access later, and why you should be prepared for investors to ask you these same questions. This series will benefit any company new to the U.S. market, or looking to launch in the U.S.
PART 3 OF 3
Future-Proofing: How to Prepare a Value-Based Market Access Strategy
Market access considerations continue to evolve in the highly dynamic U.S. market. With an increasing focus on value delivery, Part 3 will discuss the different ways to measure and demonstrate value, the interplay between FDA and CMS on such value propositions, and strategies for payer engagement.